NEW YORK--(BUSINESS WIRE)--Neuro-Hitech, Inc. (NASDAQ: NHPI) today announced that its U.S. Phase II clinical trial of Huperzine A is fully enrolled. In December 2006, a decision was made to increase enrollment from the original target of 150 by an additional 60 patients. Enrollment was recently concluded with 210 subjects at 35 trial sites throughout the U.S.
